Y-Intercept (HK)’s Royalty Pharma RPRX Stock Holding History

Y-Intercept (HK)’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-73,339	Closed	-$3.52M	–	2098
2026 Q1	$3.52M	Buy	73,339 +68,079	+1,294%	+$2.98M	0.07%	465
2025 Q4	$203K	Sell	5,260 -106,824	-95%	-$4.07M	﹤0.01%	1438
2025 Q3	$3.95M	Sell	112,084 -37,988	-25%	-$1.38M	0.09%	288
2025 Q2	$5.41M	Buy	150,072 +142,423	+1,862%	+$4.72M	0.13%	198
2025 Q1	$238K	Buy	+7,649	New	+$242K	0.02%	990
2024 Q4	–	Sell	-30,853	Closed	-$873K	–	1589
2024 Q3	$873K	Sell	30,853 -7,200	-19%	-$199K	0.05%	508
2024 Q2	$1M	Buy	38,053 +995	+3%	+$27.6K	0.06%	488
2024 Q1	$1.13M	Buy	37,058 +26,354	+246%	+$777K	0.08%	340
2023 Q4	$301K	Sell	10,704 -16,158	-60%	-$444K	0.03%	822
2023 Q3	$729K	Sell	26,862 -21,149	-44%	-$628K	0.07%	420
2023 Q2	$1.48M	Buy	+48,011	New	+$1.63M	0.16%	168
2023 Q1	–	Sell	-16,076	Closed	-$635K	–	1482
2022 Q4	$635K	Buy	+16,076	New	+$671K	0.09%	341
2021 Q1	–	Sell	-11,226	Closed	-$555K	–	773
2020 Q4	$555K	Buy	+11,226	New	+$476K	0.23%	125

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Y-Intercept (HK)'s RPRX Position: Q2 2026 in Review

Y-Intercept (HK) sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 73,339 shares — an estimated $3.52M sold.

Y-Intercept (HK) first reported a position in RPRX in Q4 2020 and held it in 13 quarters. The position peaked at $5.41M in Q2 2025. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Y-Intercept (HK) reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
Y-Intercept (HK) sold 73,339 Royalty Pharma shares in Q2 2026, an estimated $3.52M.
Y-Intercept (HK) first reported a position in Royalty Pharma in Q4 2020 and held it in 13 quarters.
Y-Intercept (HK)'s Royalty Pharma position peaked at $5.41M in Q2 2025.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.